Financings in Brief: Aksys, Ltd.
This article was originally published in The Gray Sheet
Aksys, Ltd.: Commences initial offering of 3.6 mil. shares of common stock for $16 each. Proceeds will be used to gear up manufacturing and for commercialization of the firm's lead product, the PHD automated personal hemodialysis system, designed to enable patients to perform hemodialysis "on a daily basis in a self-care setting." Additional proceeds will go toward "working capital and other general corporate purposes," the firm states. Smith Barney, Piper Jaffray and Vector Securities International served as underwriters for the offering...
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.